ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Qualigen Therapeutics, Inc. (QLGN) stock surged +7.93%, trading at $3.81 on NASDAQ, up from the previous close of $3.53. The stock opened at $3.36, fluctuating between $3.36 and $4.04 in the recent session.
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Employees | 4 |
Beta | -0.03 |
Sales or Revenue | $0.00 |
5Y Sales Change% | -0.906% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |